Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||triple-receptor negative breast cancer||not applicable||Capivasertib + Paclitaxel||Phase II||Actionable||In a Phase II trial, Capivasertib (AZD5363) in combination with Taxol (paclitaxel) as first-line therapy resulted in improved median progression-free survival (5.9 vs 4.2 months, HR=0.75, p=0.06) and median overall survival (19.1 vs 12.6 months, HR=0.64, p=0.02) compared to placebo in patients with metastatic triple-negative breast cancer (J Clin Oncol 36, no. 15_suppl (May 20 2018) 1007-1007; NCT02423603).||detail...|
|PubMed Id||Reference Title||Details|
|AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial.||Full reference...|